A study of AAV gene therapy in monkeys proposes that integrated vectors may drive long-term transgene expression.
References
Greig, J. A. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-01974-7 (2023).
Nathwani, A. C. et al. Blood 132 (Suppl. 1), 491 (2018).
Pasi, K. J. et al. N. Engl. J. Med. 382, 29–40 (2020).
George, L. A. et al. N. Engl. J. Med. 385, 1961–1973 (2021).
Muhuri, M., Levy, D. I., Schulz, M., McCarty, D. & Gao, G. Mol. Ther. 30, 1364–1380 (2022).
Nakai, H. et al. J. Virol. 75, 6969–6976 (2001).
Sun, X. et al. Hum. Gene Ther. 21, 750–761 (2010).
Fong, S. et al. Nat. Med. 28, 789–797 (2022).
Sabatino, D. E. et al. Mol. Ther. 30, 2646–2663 (2022).
Dalwadi, D. A. et al. Mol. Ther. 29, 2898–2909 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.Z. declares no competing interests. I.G.F. was an employee of a contract research organization offering vector integration services.
Rights and permissions
About this article
Cite this article
Zabaleta, N., Gil-Farina, I. Tracing the fate of AAV vectors in the body. Nat Biotechnol (2023). https://doi.org/10.1038/s41587-023-02047-5
Published:
DOI: https://doi.org/10.1038/s41587-023-02047-5
- Springer Nature America, Inc.